[go: up one dir, main page]

DE60234778D1 - Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis - Google Patents

Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis

Info

Publication number
DE60234778D1
DE60234778D1 DE60234778T DE60234778T DE60234778D1 DE 60234778 D1 DE60234778 D1 DE 60234778D1 DE 60234778 T DE60234778 T DE 60234778T DE 60234778 T DE60234778 T DE 60234778T DE 60234778 D1 DE60234778 D1 DE 60234778D1
Authority
DE
Germany
Prior art keywords
sepsis
prevention
treatment
inhibitors
syndrone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60234778T
Other languages
English (en)
Inventor
Charles A Dinarello
Giamila Fantuzzi
Soo-Hyun Kim
Leonid Reznikov
Menachem Rubinstein
Daniela Novick
Boris Schwartsburd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of DE60234778D1 publication Critical patent/DE60234778D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60234778T 2001-05-16 2002-05-16 Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis Expired - Lifetime DE60234778D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29146301P 2001-05-16 2001-05-16
PCT/US2002/015556 WO2002092008A2 (en) 2001-05-16 2002-05-16 Use of il-18 inhibitors for the treatement or prevention of sepsis

Publications (1)

Publication Number Publication Date
DE60234778D1 true DE60234778D1 (de) 2010-01-28

Family

ID=23120395

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60234778T Expired - Lifetime DE60234778D1 (de) 2001-05-16 2002-05-16 Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis

Country Status (20)

Country Link
US (1) US20030008822A1 (de)
EP (1) EP1425028B1 (de)
JP (1) JP4502580B2 (de)
KR (1) KR100877033B1 (de)
CN (1) CN100556450C (de)
AT (1) ATE451930T1 (de)
BR (1) BR0210904A (de)
CA (1) CA2446942C (de)
CY (1) CY1109713T1 (de)
DE (1) DE60234778D1 (de)
DK (1) DK1425028T3 (de)
EA (1) EA009125B1 (de)
ES (1) ES2334773T3 (de)
HK (1) HK1066723A1 (de)
IL (2) IL158866A0 (de)
MX (1) MXPA03010575A (de)
PT (1) PT1425028E (de)
SI (1) SI1425028T1 (de)
UA (1) UA85531C2 (de)
WO (1) WO2002092008A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2424983A1 (en) 2000-10-11 2002-04-18 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
JP5074030B2 (ja) 2003-05-13 2012-11-14 メルク セローノ ソシエテ アノニム Ｉｌ−１８結合タンパク質の活性変異体とその医学的応用
EP1628530B8 (de) 2003-05-15 2012-08-01 Genentech, Inc. Verfahren und zubereitungen zur vorbeugung und behandlung von sepsis
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
WO2005110450A1 (ja) * 2004-05-17 2005-11-24 Keio University 医薬組成物及び治療方法
FI116804B (fi) * 2004-05-18 2006-02-28 Ekspansio Engineering Ltd Oy Materiaalikappaleiden eri suuntiin osoittavien pintojen optinen tarkastus
WO2006128908A1 (en) 2005-06-03 2006-12-07 Ares Trading S.A. Production of recombinant il-18 binding protein
RS52273B (en) 2005-06-10 2012-10-31 Ares Trading S.A. PROCESS FOR PURIFICATION OF IL-18 BINDING PROTEIN
EP2143436B1 (de) 2007-03-28 2015-07-29 Universidad de Barcelona Cd6 produkt zur behandlung von infektionserkrankungen und entsprechende entzündungsprozesse
CL2008002153A1 (es) 2007-07-24 2009-06-05 Amgen Inc Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r.
KR20140018837A (ko) 2010-08-27 2014-02-13 스템 센트알엑스 인코포레이티드 노텀 단백질 조절 인자 및 사용 방법
WO2012112007A2 (ko) * 2011-02-18 2012-08-23 주식회사 스템디알 Ｓｉｒｔ１ 발현 유도 물질을 포함하는 패혈증 또는 패혈증 쇼크의 예방 또는 치료용 조성물.
JP6262721B2 (ja) 2012-05-11 2018-01-17 ジェムバックス アンド カエル カンパニー，リミティド 敗血症の予防用または治療用の組成物
EP3428181A3 (de) 2012-05-11 2019-02-20 KAEL-GemVax Co., Ltd. Entzündungshemmende peptide und zusammensetzung damit
EP2873678B8 (de) 2012-07-11 2024-07-17 Gemvax & Kael Co., Ltd. Konjugat enthaltend ein zellpenetrierendes peptid und zusammensetzungen davon
CN105263508B (zh) 2013-04-19 2019-10-25 珍白斯凯尔有限公司 治疗和预防缺血性损伤的组合物
RU2725744C2 (ru) 2013-06-07 2020-07-03 Джемвакс Энд Каэл Ко., Лтд. Биологические маркеры, которые могут быть использованы в иммунотерапии рака
WO2014204281A1 (ko) 2013-06-21 2014-12-24 주식회사 카엘젬백스 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법
DK3041864T3 (da) * 2013-09-05 2021-09-27 Ab2 Bio Sa Il-18-bindende protein (il-18bp) ved inflammatoriske sygdomme
RU2661596C2 (ru) 2013-10-23 2018-07-17 Джемвакс Энд Каэл Ко., Лтд. Композиция для лечения и профилактики доброкачественной гиперплазии простаты
EP3072519B1 (de) 2013-11-22 2020-08-19 Gemvax & Kael Co., Ltd. Peptid mit angiogenesehemmender wirkung und zusammensetzung damit
WO2015093854A1 (ko) 2013-12-17 2015-06-25 주식회사 카엘젬백스 전립선 암 치료용 조성물
GB201400997D0 (en) * 2014-01-21 2014-03-05 Vib Vzw Targeting of interleukin-1 and -18 in treatment of septic shock
KR102373603B1 (ko) 2014-04-11 2022-03-14 주식회사 젬백스앤카엘 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
WO2015167067A1 (ko) 2014-04-30 2015-11-05 주식회사 카엘젬백스 장기, 조직 또는 세포 이식용 조성물, 키트 및 이식 방법
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
US10835582B2 (en) 2015-02-27 2020-11-17 Gemvax & Kael Co. Ltd. Peptide for preventing hearing loss, and composition comprising same
MY194040A (en) 2015-03-05 2022-11-09 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
EP3318265B1 (de) 2015-07-02 2021-08-18 Gemvax & Kael Co., Ltd. Peptid mit antiviraler wirkung und zusammensetzung damit
CN117018162A (zh) 2016-04-07 2023-11-10 珍白斯凯尔有限公司 具有增加端粒酶活性和延长端粒的效果的肽以及组合物
EP3541407A1 (de) 2016-11-18 2019-09-25 Universitat de Barcelona Kombinierte cd6- und imipenem-therapie zur behandlung von infektionskrankheiten und damit verbundenen entzündungsprozessen
CN107715105B (zh) * 2017-10-26 2020-11-24 重庆医科大学 Il-34在制备治疗或预防脓毒症药物中的应用
CN109954131B (zh) * 2017-12-14 2023-05-02 深圳市中科艾深医药有限公司 一种肿瘤坏死因子相关凋亡诱导配体拮抗剂作为脓毒血症治疗药物的应用
CN111012899A (zh) * 2020-01-08 2020-04-17 重庆医科大学 Il-38的新用途
WO2022232698A2 (en) * 2021-04-30 2022-11-03 The Children's Hospital Of Philadelphia Compositions and methods of treating sepsis in patients using anti-light antibodies
CN115154581A (zh) * 2022-05-31 2022-10-11 八加一药业股份有限公司 选择性TNFR1拮抗肽Hydrostatin-SN10在治疗脓毒症中的应用
CN115754304A (zh) * 2022-11-24 2023-03-07 重庆医科大学 骨形态蛋白-7作为生物标志物在脓毒血症诊断、预后或治疗监测中的用途
WO2024148232A2 (en) 2023-01-06 2024-07-11 Alector Llc Anti-il18 binding protein antibodies and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
EP0504257A4 (en) * 1989-11-29 1993-03-03 Brigham And Women's Hospital (ala il-8) 77 as a leukocyte adhesion inhibitor
US5536637A (en) * 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
ATE317381T1 (de) * 1996-10-11 2006-02-15 Warner Lambert Co Sulfonamid-substituierte asparaginsäuren als inhibitoren von interleukin-1beta-konvertierenden enzymen
WO1998041232A2 (en) * 1997-03-18 1998-09-24 Basf Aktiengesellschaft Compositions for modulating responsiveness to corticosteroids
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
KR101111103B1 (ko) * 2000-02-10 2012-02-13 아보트 러보러터리즈 사람 인터류킨-18에 결합하는 항체 및 이를 제조하고 사용하는 방법
TR200502508T2 (tr) * 2000-02-21 2007-04-24 Applied Research Systems Ar� Holding N.V. IL-18 İnhibitörlerinin kullanımı.
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
US20030008822A1 (en) 2003-01-09
EA200301248A1 (ru) 2005-06-30
EA009125B1 (ru) 2007-10-26
CA2446942C (en) 2010-07-20
CN100556450C (zh) 2009-11-04
JP2004531546A (ja) 2004-10-14
WO2002092008A3 (en) 2004-04-08
MXPA03010575A (es) 2005-03-07
KR100877033B1 (ko) 2009-01-07
IL158866A0 (en) 2004-05-12
DK1425028T3 (da) 2010-03-01
ES2334773T3 (es) 2010-03-16
BR0210904A (pt) 2005-08-16
CA2446942A1 (en) 2002-11-21
KR20040045400A (ko) 2004-06-01
EP1425028A4 (de) 2006-03-01
CY1109713T1 (el) 2014-08-13
SI1425028T1 (sl) 2010-02-26
ATE451930T1 (de) 2010-01-15
JP4502580B2 (ja) 2010-07-14
HK1066723A1 (en) 2005-04-01
CN1529611A (zh) 2004-09-15
EP1425028A2 (de) 2004-06-09
UA85531C2 (uk) 2009-02-10
WO2002092008A2 (en) 2002-11-21
EP1425028B1 (de) 2009-12-16
PT1425028E (pt) 2010-01-06
IL158866A (en) 2011-01-31

Similar Documents

Publication Publication Date Title
DE60234778D1 (de) Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis
PH12021551686A1 (en) Pcsk9 inhibitors and methods of use thereof
EA200500856A1 (ru) Новые химические соединения
DE60229975D1 (de) Nf-kb-inhibitoren
NO20030895D0 (no) Ny anvendelse av dipeptidyl peptidase IV inhibitorer
ATE345331T1 (de) Verbindungen verwendbar für die behandlung von entzündungskrankheiten
TNSN06138A1 (fr) Inhibitors of the mutant form of kit
WO2002030353A3 (en) NF-λB INHIBITORS
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
DE60329326D1 (de) Tace inhibitoren
DE60328603D1 (de) Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren
SE0102808D0 (sv) New compounds
EA200501528A1 (ru) Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний
DE60040089D1 (de) Menschliches homolog aus der familie der metalloproteasen
ATE534380T1 (de) Glepp-1-hemmer bei der behandlung von autoimmun- und/oder entzündungskrankheiten
DE60224004D1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
ATE423129T1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
DE60122898D1 (de) Aldosteronantagonist und cyclooxygenase-2 hemmer-kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten
ATE333869T1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
EA200400296A1 (ru) Применение ингибиторов il-18 при расстройствах в виде гиперчувствительности
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
DE60142804D1 (de) Menschliche hodenspezifische Serin/Threonin-Kinase
DE602005013805D1 (de) Verwendung von il-17f zur behandlung und/oder prävention von neurologischen erkrankungen
ATE394117T1 (de) Verwendung von cc-chemokine ccl5/rantes mutanten zur behandlung von lebererkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition